AbbVie Q2 2024 Adj EPS $2.65 Beats $2.57 Estimate, Sales $14.462B Beat $14.027B Estimate
Portfolio Pulse from Benzinga Newsdesk
AbbVie reported Q2 2024 adjusted EPS of $2.65, beating the estimate of $2.57. Sales were $14.462 billion, surpassing the expected $14.027 billion.
July 25, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie reported better-than-expected Q2 2024 earnings and sales, with adjusted EPS of $2.65 beating the $2.57 estimate and sales of $14.462 billion surpassing the $14.027 billion forecast.
AbbVie's Q2 2024 earnings and sales both exceeded analyst expectations, which is likely to positively impact the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100